The IGSF8 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population for functional studies of the IGSF8 gene in human esophageal squamous cell carcinoma. This product comprises a heterogeneous pool of KYSE-30 cells with targeted disruption of the IGSF8 locus via CRISPR/Cas9. The loss-of-function model allows researchers to dissect tumor-suppressive roles of IGSF8 without clonal variability, providing a robust tool for gene function analysis in a polyclonal background.
The parental KYSE-30 cell line is a well-differentiated human esophageal squamous cell carcinoma cell line derived from an esophageal epithelial carcinoma. It maintains key epithelial characteristics and dysregulated signaling pathways relevant to esophageal carcinogenesis, making it a widely used model for studying esophageal squamous cell carcinoma biology, drug responses, and metastatic mechanisms. Its well-characterized growth properties and receptor expression profiles enable genetic manipulation and functional assays.
IGSF8 (also known as EWI-2) is an immunoglobulin superfamily member that associates with tetraspanins CD9 and CD81 within tetraspanin-enriched microdomains. It functions as a negative regulator of integrin-mediated cell adhesion, migration, and proliferation by directly interacting with integrins ??3??1 and ??6??1. This interaction stabilizes membrane microdomains and attenuates downstream signaling through focal adhesion kinase (FAK) and Src kinase, leading to reduced activation of the PI3K-Akt pathway and diminished RhoA-driven cytoskeletal reorganization. By dampening FAK and Akt phosphorylation, IGSF8 suppresses cancer cell invasion. Upstream regulators include epidermal growth factor (EGF), integrin ligands, TGF-??, and oncogenic KRAS/PIK3CA, all of which can influence IGSF8 expression and localization. Disruption of IGSF8 relieves these brakes, enhancing invasive properties.
Disruption of IGSF8 in the KYSE-30 esophageal squamous cell carcinoma model is expected to relieve inhibition on integrin signaling, leading to enhanced FAK phosphorylation, Akt activation, and RhoA-mediated motility. This mimics metastatic phenotypes seen in esophageal and other cancers where IGSF8 is frequently downregulated. The polyclonal knockout population provides a physiologically relevant system to examine how IGSF8 loss alters cell adhesion dynamics, invasion, and signal transduction, offering insights into tumor progression.
Researchers can use this knockout model in assays including Western blot for IGSF8 and phospho-Akt, cell migration and invasion assays (e.g., Boyden chamber), FAK phosphorylation analysis, proliferation assays, co-immunoprecipitation of IGSF8 with tetraspanins, and flow cytometry for integrin surface expression. These applications support investigation of IGSF8??s role in esophageal squamous cell carcinoma metastasis and tumor suppression, as well as screening of compounds targeting integrin or tetraspanin pathways. For technical inquiries, please contact Ascent Research.
